Articles tagged with Cancer Stem Cells
Researchers discovered a way to supercharge natural killer cells into specialized form that can reside inside tissues and kill tumor cells. The therapy slowed the growth of various solid tumors when tested in mice, offering potential new approach for cancer treatment.
A new study published in Genes & Diseases journal reveals that lncRNA ROLLCSC promotes ferroptosis resistance and metastasis in lung cancer by regulating lipid metabolism. The researchers identified ROLLCSC as a therapeutic target, suggesting potential treatments for advanced lung adenocarcinoma.
Researchers found that BEX2 levels were associated with weaker stemness, reduced tumor-forming ability, lower drug resistance, and less invasive behavior. BEX2 destabilizes MCL1, dampening Hedgehog signaling, a pathway closely tied to cancer stem cell maintenance.
Researchers explore the role of pseudogene-derived lncRNAs in governing cancer stem cell biology, highlighting their mechanisms and therapeutic targeting. These non-coding RNAs modulate CSC dynamics through various pathways, influencing tumor initiation and progression.
Researchers generated a comprehensive view of DNA methylation abnormalities in human MDS HSCs, uncovering a novel TET2-GFI1 axis that suppresses malignant transformation. The study identifies key hematopoietic regulators and provides a panoramic view of DNA methylation disruption in MDS.
A Johns Hopkins study reveals that cysteine metabolism shapes CD8+ T-cell function, with implications for boosting cancer-killing immune responses. Limiting cysteine in laboratory models enhanced anti-tumor immunity but impaired T-cell expansion and weakened anti-tumor activity.
Researchers review EMT mechanisms and its impact on GBM progression, highlighting key signaling pathways and GSCs. EMT-targeted therapies offer promising strategies to disrupt tumor growth and enhance immune responses.
Researchers at Kyoto University identified five molecular subtypes of colorectal cancer stem cells and developed a practical prognostic indicator, the general colorectal cancer signature (GCS), to predict patient outcomes. The GCS was validated with a novel orthotopic xenograft mouse model and showed promising clinical significance.
Researchers at UNIGE and HUG have developed CAR-T cells capable of destroying glioblastoma cells by targeting specific proteins present in the tumour environment. The new approach has shown promising results in animal models, paving the way for clinical trials in humans.
This study reveals that GPNMB modifies the tumor microenvironment by repurposing macrophages into immunosuppressive tumor-associated macrophages. The interaction between GPNMB and Siglec-9 enables this reprogramming, leading to increased cancer cell motility and invasiveness.
Researchers have identified CDX1 and CDX2 as key molecules that counteract β-catenin and suppress stemness in colon cancer. Deletion or overexpression of these proteins increased tumor aggressiveness and expression of cancer stemness-related genes, suggesting a potential therapeutic target.
A newly developed AI-based tool uses protein expression to create a stemness index that analyzes tumor similarity to pluripotent stem cells. The model predicts tumor aggressiveness and identifies potential targets for new therapies, offering hope for improved cancer treatment.
The interplay between exosomes and metabolic reprogramming shapes breast cancer progression and resistance. Targeting this axis offers novel diagnostic and therapeutic strategies, including exosome-based liquid biopsy techniques and combination therapies.
Researchers discovered a new tumor-suppressive response targeting RNA Polymerase 1, inhibiting cancer cell growth and enhancing responsiveness to immunotherapies. The Pol 1 inhibitor BOB-42 reduced tumor growth by up to 77% in melanoma and colorectal cancers.
Researchers at MD Anderson have made significant progress in treating non-small cell lung cancer (NSCLC) by combining chemotherapy, immunotherapy, and surgery. They found that pre-surgical combination therapy showed promising results, with high rates of pathological complete response and major pathological response.
Researchers have developed a new compound, SHP1705, that selectively attacks glioblastoma stem cells by hijacked circadian clock proteins. The compound was found to be safe and well-tolerated in humans during a phase 1 clinical trial.
The MEDiCS project, led by Prof. José Luis Mascareñas, aims to develop a new anticancer agent targeting cancer stem cells using ruthenium-based metallic complexes. The €2.5 million funded project will progress the technology through preclinical phase and human clinical trials for pancreatic and colon cancers.
Researchers found that SLC27A5 downregulates PABPC1, reducing the utilization frequency of METTL14-dPAS and shifting to shorter 3'UTRs, leading to HCC stemness inhibition. This study suggests targeting SLC27A5-induced APA or METTL14-US as a novel therapeutic approach for impeding HCC progression.
Researchers have discovered a new druggable cancer target, NPM1, which is expressed on the surface of malignant AML cells. Monoclonal antibodies targeting NPM1 showed robust anti-tumor activity in multiple in vivo models of AML, with no apparent toxicity to non-cancerous blood cells and stem cells.
A new study suggests that a key enzyme in lipid metabolism, ELOVL2, plays a critical role in maintaining a healthy immune system as we age. Decreased activity of the enzyme speeds up immune system changes associated with aging, impairing the development of B cells and altering the expression of cancer-associated genes.
Aging-associated mutations in the Dnmt3a gene boost mitochondria power in blood stem cells, leading to clonal hematopoiesis. New mitochondrial-targeting drugs show promise in treating age-related illnesses by selectively weakening mutated cells without impacting normal ones.
A UC Riverside-led study found that adult stem cells rely on histone chaperones to maintain their regenerative capacity. The researchers discovered that disrupting these proteins can lead to specific changes in stem cell identity, potentially guiding them into desired cell types.
Researchers identified CSC characteristics, endogenous regulatory mechanisms, niche factors, and targeting strategies for digestive system tumors. Understanding CSCs is crucial for developing breakthrough treatments.
A Phase 3 trial found that ChemoID improves objective response rates, median progression-free survival, and duration of response in patients with recurrent platinum-resistant ovarian cancer. The test identifies effective treatments by challenging cancer stem cells against specific anticancer drugs.
Researchers have developed drug-delivering aptamers that target and kill leukemia stem cells, reducing the need for high doses of chemotherapy. The aptamers pair well with existing drugs like daunorubicin to deliver a targeted one-two knockout punch against cancer.
Researchers have developed a way to activate adult stem cells from human bone marrow, enabling their expansion outside the body for use in bone marrow regeneration. The new method significantly improves transplant success rates for patients with genetic disorders or those who require a bone marrow transplant.
Researchers found genetic changes in frequent blood donors that enable them to respond well to blood loss, promoting healthy stem cell growth. In contrast, preleukemic mutations associated with blood cancer were not favored by regular donation.
Researchers discovered a molecular switch, FLI-1, essential for blood stem cells to enter an activated state. Transiently producing FLI-1 in quiescent adult mobilized bone marrow stem cells activates them, improving their ability to expand and restore the blood cell supply in a new host.
This review highlights the critical role of ubiquitination in governing cancer stem cell (CSC) functionality, shedding light on potential therapeutic targets. The Ub system regulates key pathways essential for CSC maintenance and survival, particularly through E3 ubiquitin ligases and deubiquitinases.
Researchers from UC San Diego will present cutting-edge solutions to address global challenges such as climate change and human longevity. The event features a film premiere and thought-provoking presentations on topics like capturing carbon and democratizing health data.
Researchers at UCSF have discovered that human lung tissue contains hematopoietic stem cells (HSCs) capable of producing red blood cells, platelets, and immune cells. The finding suggests the lungs could be a potent source for life-saving stem cell transplants, particularly for patients with leukemia.
Researchers combine radiation with a plant-derived compound to combat glioblastoma, forcing cancer cells into a dormant state. The approach significantly slows tumor growth and improves survival in mice models, offering a potential new avenue for combating this deadly form of brain cancer.
Researchers discover that the gene HMGA1 'opens' regions of the genome to activate stem cell genes, leading to tumor development and progression. High levels of HMGA1 also allow mutant tumor cells to escape detection by immune cells.
A new nanomedicine, ZnDHT NM, selectively targets cancer stem-like cells (CSCs) and tumor cells, promoting CSC differentiation while inhibiting EMT. This approach also leads to the release of toxic compounds in tumor cells, inducing apoptosis/ferroptosis pathways.
A team of researchers at Queen Mary University of London discovered that disrupting a single amino acid in the vimentin protein makes breast cancer cells behave like stem cells. This mutation promotes tumour growth and increases cancer stemness in an oestrogen-independent manner.
A new case report reveals a rare and aggressive form of leukemia developing from donor cells nine years after a stem cell transplant. The disease, driven by genetic mutations in key genes, progresses despite intensive treatment and ultimately proves fatal.
Researchers found that glioblastoma stem cells are co-localized with myeloid-derived suppressor cells, promoting tumor growth and aggressiveness. The study identified key molecules, such as IL-6 and IL-8, that attract and activate MDSCs, providing new potential therapeutic targets.
Researchers have developed a novel stem cell treatment strategy for leptomeningeal brain metastasis, a severe form of metastatic brain cancer. The new therapy, which combines allogeneic dual stem cells with oncolytic herpes simplex virus and single chain variable fragment of anti-PD-1, shows promise in preclinical models.
A preclinical study by Weill Cornell Medicine investigators found that an immune protein called the inflammasome helps prevent blood stem cells from becoming malignant by removing certain receptors and blocking cancer gene activity. The study suggests that targeting the earliest stages of cancer may lead to new therapies.
Researchers at UCSF have discovered a new type of stem cell in the young brain that can form cells found in tumors, shedding light on how adult brain cells grow and develop into deadly brain cancers. The study provides a comprehensive roadmap for understanding healthy brain development, which could lead to better treatments for conditi...
A preclinical study suggests the experimental compound K884 can restore lost muscle function in Duchenne muscular dystrophy (DMD) patients by strengthening muscle repair. The drug targets specific enzymes, allowing muscle stem cells to develop into functional tissue.
Recent studies suggest HBV infection is associated with liver cancer stem cells, but the exact mechanisms are unclear. This study investigates the role of HBV infection in regulating the stemness of HCCs and its link to drug resistance.
Researchers created a comprehensive map of blood cell changes from fetal development to old age, finding that leukemia cells can reflect young or old blood cell production. Patients with leukemia whose cells resemble young blood cells have a worse prognosis.
Mesenchymal stem cells (MSCs) show promise in delivering treatments directly to cancer cells and boosting the immune system's fight against cancer. However, ongoing research highlights challenges related to MSC behavior, including variability in their effects and potential to create conditions that support tumor growth.
Researchers analyzed chromosomal chaos in leukemia cells and found that genetic and non-genetic factors drive functional heterogeneity. They identified therapeutic targets and alternatives for resistant subclones, providing a model for early identification of leukemia stem cells.
A team of researchers at the University of Toronto has discovered two distinct subtypes of glioblastoma cancer stem cells, each with unique genetic vulnerabilities. By targeting these vulnerabilities, a more effective treatment approach may be developed, improving prognosis for patients with this lethal brain cancer.
Researchers at MD Anderson Cancer Center have made significant advancements in understanding tissue regeneration, with a focus on epigenetic regulation and retrotransposon suppression. MicroRNAs have also been identified as potential biomarkers for COVID-19 severity in cancer patients, while a novel protein complex drives lung regenera...
Researchers tracked the long-term dynamics of transplanted stem cells in patients' bodies up to three decades post-transplant. They found that younger donors produce more vital stem cells, while older donors experience reduced immunity and higher relapse risk. The study provides new insights into donor selection and transplant success.
A new study from the University of Texas at Arlington suggests that analyzing RNA in urine can show changes in cell types, revealing early signs of cancer and other diseases. This method could help clinicians detect problems earlier when they are more easily treated without invasive procedures.
Glioblastoma, the most malignant primary brain tumour, has an 18-month median survival rate despite treatment. New research from the University of Ottawa suggests a drug used to slow ALS progression may also suppress glioblastoma's self-renewing cancerous stem cells.
Researchers at Umea University have discovered how embryonic stem cells transition into specialized cells, highlighting the importance of LSD1 protein in cancer development. The study suggests that targeting only LSD1's enzymatic activity may not be enough for cancer treatments to be effective.
A novel molecular glue, LXH-3-71, was discovered to degrade PHGDH by facilitating formation of a dynamic chimera with the DDB1-CRL E3 ligase. This interaction modulates the stemness of colorectal cancer cells both in vitro and in vivo.
Researchers identified key control sites regulating gene expression in cells, including those controlling ancient viral sequences. Mutating these sites caused defects in cell differentiation and survival, as well as spurious activation of genes across the genome.
A new study reveals that fasting helps regenerate and heal intestinal injuries, but also increases the risk of developing early-stage intestinal tumors in mice. The researchers identified a pathway enabling this enhanced regeneration, which is activated during refeeding after fasting.
Researchers discovered that blocking Cxcr4 in mice reduced white fat tissue, while estrogen therapy could be effective with lower doses. The study offers promising avenues for understanding healthy and unhealthy fat tissue development.
Texas A&M researchers are investigating the use of extracellular vesicles to deliver immune-suppressing proteins, potentially reducing the immune system's attack on insulin-producing beta-cells. The goal is to develop a novel treatment for type 1 diabetes, which currently has only lifelong insulin therapy as an approved option.
Researchers at the University of Helsinki have created cells that can't grow uncontrolledly, which could lead to new and safer cell therapies for hereditary diseases, myocardial infarction, and other conditions. The innovation uses thymidine supplementation to regulate cell division, eliminating the risk of cancer.
Researchers found that a cancer drug can restore phagocytosis, a process crucial for brain health, in individuals with Rett syndrome by targeting microglia. The study highlights the potential therapeutic target of microglia in neurological conditions and may lead to new treatments.
Researchers identified genetic and metabolic characteristics of leukaemic stem cells, including a specific iron utilisation process that can be blocked to kill these cells without harming healthy ones. This breakthrough paves the way for new therapeutic strategies to combat leukemia.
Researchers at University of California San Diego have found that genetically modified NK-cell therapy can effectively target and treat hepatocellular carcinoma, a highly treatment-resistant form of solid tumor. The therapy works by disabling the inhibitory protein TGF-β, allowing immune cells to kill cancer more efficiently.